PRESS RELEASE published on 01/26/2026 at 18:00, 1 month 27 days ago ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.12.25. ABIVAX annonce le nombre d'actions et de droits de vote au 31.12.25. Société de biotechnologie axée sur les traitements thérapeutiques dans les maladies inflammatoires chroniques Droits De Vote Biotechnologie Actions Abivax Maladies Inflammatoires
BRIEF published on 01/07/2026 at 22:10, 2 months 14 days ago Abivax unveils its objectives for 2026 Abivax Obefazimod Phase 3 2026 RCH
BRIEF published on 01/07/2026 at 22:10, 2 months 14 days ago Abivax dévoile ses objectifs pour 2026 Abivax Obefazimod Phase 3 2026 RCH
BRIEF published on 01/07/2026 at 22:10, 2 months 14 days ago Abivax dévoile ses plans stratégiques pour 2026 Dépôt Réglementaire Perspectives D'Abivax Pour 2026 Marché De La Colite Ulcéreuse Essais Cliniques Sur L'obefazimod Recherche Sur La Maladie De Crohn
BRIEF published on 01/07/2026 at 22:10, 2 months 14 days ago Abivax Reveals Strategic Plans for 2026 Regulatory Filing Abivax 2026 Outlook Ulcerative Colitis Market Obefazimod Trials Crohn’s Disease Research
PRESS RELEASE published on 01/07/2026 at 22:05, 2 months 14 days ago Abivax présente ses perspectives pour 2026 Abivax présente ses perspectives pour 2026, annonçant des nouveautés dans le traitement de la rectocolite hémorragique, les progrès des essais ABTECT-UC et ENHANCE-CD, et l'avancement de son portefeuille de candidats médicaments Abivax Maladies Inflammatoires Chroniques Rectocolite Hémorragique Essais Cliniques Perspectives 2026
PRESS RELEASE published on 01/07/2026 at 22:05, 2 months 14 days ago Abivax Provides 2026 Corporate Outlook Abivax provides 2026 corporate outlook, highlighting market insights, trial progress, and pipeline advancements in treating chronic inflammatory diseases like UC and CD Abivax Chronic Inflammatory Diseases 2026 Corporate Outlook UC CD
BRIEF published on 12/18/2025 at 22:10, 3 months 3 days ago Abivax rejoint l'indice Nasdaq Biotechnology Biotechnologie Abivax Obefazimod Rectocolite Hémorragique Nasdaq Biotechnology
BRIEF published on 12/18/2025 at 22:10, 3 months 3 days ago Abivax joins the Nasdaq Biotechnology index Biotechnology Abivax Obefazimod Ulcerative Colitis Nasdaq Biotechnology
BRIEF published on 12/18/2025 at 22:10, 3 months 3 days ago Abivax Joins Nasdaq Biotechnology Index Biotechnology Abivax Obefazimod Ulcerative Colitis Nasdaq Biotechnology Index
Published on 03/20/2026 at 13:30, 2 days 8 hours ago Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 2 days 9 hours ago CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals
Published on 03/22/2026 at 12:23, 9 hours 35 minutes ago Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 1 day 23 hours ago Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 2 days ago Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 2 days ago Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 19:00, 2 days 2 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 2 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 3 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 3 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
